Effects of lutein and omega-3 fat enriched egg consumption on visual function in older adults: Implications for age-related macular degeneration

Effects of lutein and docosahexaenoic acid enriched egg consumption in older adults: Implications for age-related macular degeneration

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN45308629

Enrollment

Registered

2018-06-28

Start date

2013-07-01

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General health of the retina and prevention of age-related macular degeneration Eye Diseases

Interventions

Avoidance of retina/eye related food items for one month prior and throughout the duration of the trial (6 weeks) including: eggs

oysters

liver (chicken, beef, veal, etc.)

sweet potato

pumpkin

carrots

kale

fish and caviar

spinach

supplements that contain zinc, choline, vitamin A, lutein, zeaxanthin and DHA. Limit retina/eye related food items for one month prior and throughout the duration of the trial (6 weeks) including: po

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Individuals between 50-80 years of age 2. Caucasian ethnicity 3. Good English written and oral communication skills

Exclusion criteria

Exclusion criteria: 1. Individuals with an egg allergy 2. Individuals diagnosed with a chronic disease (ie. diabetes, cardiovascular disease etc) 3. Individuals diagnosed with mental cognitive disorders 4. Individuals diagnosed as hypercholesterolemic 5. Individuals taking statins and other lipid lowering medications 6. Individuals diagnosed with eye related disease (i.e. glaucoma, AMD, retinitis pigmentosa, etc)

Design outcomes

Primary

Measure	Time frame
1. Self-assessed health and vision status measured using a modified version of the National Eye Institute Visual Functioning Questionnaire at PRE (week 0), DURING (week 3) and POST (week 6) assessment 2. Plasma lipid profiles (Total cholesterol, HDL-cholesterol, LDL-cholesterol, Triglycerides), measured using a Cobas C 111 Analyzer at PRE (week 0), DURING (week 3) and POST (week 6) assessment 3. Plasma fatty acids, measured by gas chromatography at PRE (week 0), DURING (week 3) and POST (week 6) assessment 4. Plasma lutein, measured using high performance liquid chromatography at PRE (week 0), DURING (week 3) and POST (week 6) assessment 5. Retina function, measured using a full field electroretinogram at PRE (week 0), DURING (week 3) and POST (week 6) assessment	—

Measure

Time frame

1. Self-assessed health and vision status measured using a modified version of the National Eye Institute Visual Functioning Questionnaire at PRE (week 0), DURING (week 3) and POST (week 6) assessment 2. Plasma lipid profiles (Total cholesterol, HDL-cholesterol, LDL-cholesterol, Triglycerides), measured using a Cobas C 111 Analyzer at PRE (week 0), DURING (week 3) and POST (week 6) assessment 3. Plasma fatty acids, measured by gas chromatography at PRE (week 0), DURING (week 3) and POST (week 6) assessment 4. Plasma lutein, measured using high performance liquid chromatography at PRE (week 0), DURING (week 3) and POST (week 6) assessment 5. Retina function, measured using a full field electroretinogram at PRE (week 0), DURING (week 3) and POST (week 6) assessment

—

Secondary

Measure	Time frame
1. Average dietary intake, measured using a 3-day food record analyzed using The Food Processor software between DURING (week 3) and POST (week 6) assessment 2. LDL/HDL particle size, measured using polyacrylamide gel electrophoresis (Lipoprint Lipoprotein Subfractions Testing System, Quantimetrix, California, US) at PRE (week 0) and POST (week 6) assessment	—

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026